PHIBRO ANIMAL HEALTH CORP-A (PAHC) Stock Price, Forecast & Analysis

USA • Nasdaq • NASDAQ:PAHC • US71742Q1067

53.07 USD
+3.07 (+6.14%)
At close: Feb 6, 2026
53.07 USD
0 (0%)
After Hours: 2/6/2026, 8:00:02 PM

PAHC Key Statistics, Chart & Performance

Key Statistics
Market Cap2.15B
Revenue(TTM)1.30B
Net Income(TTM)67.82M
Shares40.53M
Float20.28M
52 Week High56.3
52 Week Low16.16
Yearly Dividend0.48
Dividend Yield0.96%
EPS(TTM)2.8
PE18.95
Fwd PE17.24
Earnings (Next)05-05
IPO2014-04-11
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
PAHC short term performance overview.The bars show the price performance of PAHC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60 80

PAHC long term performance overview.The bars show the price performance of PAHC in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300

The current stock price of PAHC is 53.07 USD. In the past month the price increased by 33.61%. In the past year, price increased by 124.02%.

PHIBRO ANIMAL HEALTH CORP-A / PAHC Daily stock chart

PAHC Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to PAHC. When comparing the yearly performance of all stocks, PAHC is one of the better performing stocks in the market, outperforming 95.33% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

PAHC Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to PAHC. While PAHC has a great profitability rating, there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PAHC Financial Highlights

Over the last trailing twelve months PAHC reported a non-GAAP Earnings per Share(EPS) of 2.8. The EPS increased by 73.91% compared to the year before.


Industry RankSector Rank
PM (TTM) 4.85%
ROA 4.89%
ROE 21.76%
Debt/Equity 2.32
Chartmill High Growth Momentum
EPS Q2Q%61.11%
Sales Q2Q%20.89%
EPS 1Y (TTM)73.91%
Revenue 1Y (TTM)27.37%

PAHC Forecast & Estimates

9 analysts have analysed PAHC and the average price target is 43.86 USD. This implies a price decrease of -17.35% is expected in the next year compared to the current price of 53.07.

For the next year, analysts expect an EPS growth of 33.72% and a revenue growth 14.65% for PAHC


Analysts
Analysts48.89
Price Target43.86 (-17.35%)
EPS Next Y33.72%
Revenue Next Year14.65%

PAHC Ownership

Ownership
Inst Owners100.08%
Ins Owners0.52%
Short Float %5.26%
Short Ratio4.37

PAHC Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
LLY ELI LILLY & CO31.531T
JNJ JOHNSON & JOHNSON20.6578.208B
MRK MERCK & CO. INC.22.54302.633B
PFE PFIZER INC9.06154.765B
BMY BRISTOL-MYERS SQUIBB CO10.19126.196B
ZTS ZOETIS INC18.5556.153B
RPRX ROYALTY PHARMA PLC- CL A8.6125.774B
VTRS VIATRIS INC5.7616.793B
ELAN ELANCO ANIMAL HEALTH INC24.112.521B
AXSM AXSOME THERAPEUTICS INC222.919.202B

About PAHC

Company Profile

PAHC logo image Phibro Animal Health Corp. engages in the development, manufacture, and marketing of animal health and mineral nutrition products. The company is headquartered in Teaneck, New Jersey and currently employs 2,475 full-time employees. The company went IPO on 2014-04-11. The company develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. The company markets approximately 750 product lines in over 80 countries to approximately 4,200 customers. The company has three segments: Animal Health, Mineral Nutrition and Performance Products. Its Animal Health segment develops, manufactures and markets about 280 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. The Mineral Nutrition segment is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.

Company Info

PHIBRO ANIMAL HEALTH CORP-A

Glenpointe Centre East, 3Rd Floor, 300 Frank W. Burr Blvd., Suite 21

Teaneck NEW JERSEY 07666 US

CEO: Jack C. Bendheim

Employees: 1940

PAHC Company Website

PAHC Investor Relations

Phone: 12013297300

PHIBRO ANIMAL HEALTH CORP-A / PAHC FAQ

Can you describe the business of PHIBRO ANIMAL HEALTH CORP-A?

Phibro Animal Health Corp. engages in the development, manufacture, and marketing of animal health and mineral nutrition products. The company is headquartered in Teaneck, New Jersey and currently employs 2,475 full-time employees. The company went IPO on 2014-04-11. The company develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. The company markets approximately 750 product lines in over 80 countries to approximately 4,200 customers. The company has three segments: Animal Health, Mineral Nutrition and Performance Products. Its Animal Health segment develops, manufactures and markets about 280 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. The Mineral Nutrition segment is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.


What is the stock price of PHIBRO ANIMAL HEALTH CORP-A today?

The current stock price of PAHC is 53.07 USD. The price increased by 6.14% in the last trading session.


What is the dividend status of PHIBRO ANIMAL HEALTH CORP-A?

PHIBRO ANIMAL HEALTH CORP-A (PAHC) has a dividend yield of 0.96%. The yearly dividend amount is currently 0.48.


How is the ChartMill rating for PHIBRO ANIMAL HEALTH CORP-A?

PAHC has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


What sector and industry does PHIBRO ANIMAL HEALTH CORP-A belong to?

PHIBRO ANIMAL HEALTH CORP-A (PAHC) operates in the Health Care sector and the Pharmaceuticals industry.


Should I buy PAHC stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PAHC.


Can you provide the market cap for PHIBRO ANIMAL HEALTH CORP-A?

PHIBRO ANIMAL HEALTH CORP-A (PAHC) has a market capitalization of 2.15B USD. This makes PAHC a Mid Cap stock.